GILD vs. BMY
Compare and contrast key facts about Gilead Sciences, Inc. (GILD) and Bristol-Myers Squibb Company (BMY).
Performance
GILD vs. BMY - Performance Comparison
Loading graphics...
GILD vs. BMY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
GILD Gilead Sciences, Inc. | 14.96% | 36.59% | 18.68% | -1.99% | 23.63% | 29.95% | -6.70% | 7.88% | -9.92% | 2.96% |
BMY Bristol-Myers Squibb Company | 15.79% | 0.11% | 15.81% | -26.14% | 18.98% | 2.88% | 0.41% | 27.74% | -12.90% | 7.71% |
Fundamentals
GILD:
$175.80B
BMY:
$125.99B
GILD:
$6.79
BMY:
$3.46
GILD:
20.67
BMY:
17.84
GILD:
0.05
BMY:
1.02
GILD:
5.98
BMY:
2.61
GILD:
7.77
BMY:
2.26
GILD:
$29.44B
BMY:
$48.19B
GILD:
$23.79B
BMY:
$30.43B
GILD:
$12.90B
BMY:
$13.82B
Returns By Period
In the year-to-date period, GILD achieves a 14.96% return, which is significantly lower than BMY's 15.79% return. Over the past 10 years, GILD has outperformed BMY with an annualized return of 7.81%, while BMY has yielded a comparatively lower 2.90% annualized return.
GILD
- 1D
- 0.67%
- 1M
- -5.95%
- YTD
- 14.96%
- 6M
- 27.78%
- 1Y
- 29.43%
- 3Y*
- 23.25%
- 5Y*
- 20.53%
- 10Y*
- 7.81%
BMY
- 1D
- 1.78%
- 1M
- -0.98%
- YTD
- 15.79%
- 6M
- 33.50%
- 1Y
- 8.90%
- 3Y*
- 0.70%
- 5Y*
- 3.49%
- 10Y*
- 2.90%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
GILD vs. BMY — Risk / Return Rank
GILD
BMY
GILD vs. BMY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Gilead Sciences, Inc. (GILD) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| GILD | BMY | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.02 | 0.31 | +0.71 |
Sortino ratioReturn per unit of downside risk | 1.63 | 0.64 | +0.99 |
Omega ratioGain probability vs. loss probability | 1.19 | 1.08 | +0.11 |
Calmar ratioReturn relative to maximum drawdown | 2.07 | 0.25 | +1.83 |
Martin ratioReturn relative to average drawdown | 5.62 | 0.39 | +5.23 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| GILD | BMY | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.02 | 0.31 | +0.71 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.86 | 0.15 | +0.72 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.31 | 0.12 | +0.19 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.39 | 0.35 | +0.04 |
Correlation
The correlation between GILD and BMY is 0.29, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
GILD vs. BMY - Dividend Comparison
GILD's dividend yield for the trailing twelve months is around 2.27%, less than BMY's 4.03% yield.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GILD Gilead Sciences, Inc. | 2.27% | 2.57% | 3.33% | 3.70% | 3.40% | 3.91% | 4.67% | 3.88% | 3.65% | 2.90% | 2.57% | 1.27% |
BMY Bristol-Myers Squibb Company | 4.03% | 4.60% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% |
Drawdowns
GILD vs. BMY - Drawdown Comparison
The maximum GILD drawdown since its inception was -70.83%, roughly equal to the maximum BMY drawdown of -72.03%. Use the drawdown chart below to compare losses from any high point for GILD and BMY.
Loading graphics...
Drawdown Indicators
| GILD | BMY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -70.83% | -72.03% | +1.20% |
Max Drawdown (1Y)Largest decline over 1 year | -13.77% | -25.79% | +12.02% |
Max Drawdown (5Y)Largest decline over 5 years | -26.59% | -47.67% | +21.08% |
Max Drawdown (10Y)Largest decline over 10 years | -36.01% | -47.67% | +11.66% |
Current DrawdownCurrent decline from peak | -9.44% | -12.07% | +2.63% |
Average DrawdownAverage peak-to-trough decline | -22.20% | -22.40% | +0.20% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.08% | 16.06% | -10.98% |
Volatility
GILD vs. BMY - Volatility Comparison
Gilead Sciences, Inc. (GILD) and Bristol-Myers Squibb Company (BMY) have volatilities of 6.36% and 6.68%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| GILD | BMY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.36% | 6.68% | -0.32% |
Volatility (6M)Calculated over the trailing 6-month period | 18.91% | 19.39% | -0.48% |
Volatility (1Y)Calculated over the trailing 1-year period | 29.01% | 28.61% | +0.40% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 23.90% | 23.68% | +0.22% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 25.63% | 25.08% | +0.55% |
Financials
GILD vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Gilead Sciences, Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
GILD vs. BMY - Profitability Comparison
GILD - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Gilead Sciences, Inc. reported a gross profit of 6.88B and revenue of 7.93B. Therefore, the gross margin over that period was 86.8%.
BMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Bristol-Myers Squibb Company reported a gross profit of 6.24B and revenue of 12.50B. Therefore, the gross margin over that period was 49.9%.
GILD - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Gilead Sciences, Inc. reported an operating income of 2.96B and revenue of 7.93B, resulting in an operating margin of 37.4%.
BMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Bristol-Myers Squibb Company reported an operating income of 1.47B and revenue of 12.50B, resulting in an operating margin of 11.8%.
GILD - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Gilead Sciences, Inc. reported a net income of 2.18B and revenue of 7.93B, resulting in a net margin of 27.6%.
BMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Bristol-Myers Squibb Company reported a net income of 1.09B and revenue of 12.50B, resulting in a net margin of 8.7%.